Steve Worland, eFFECTOR CEO
Surprise pivot rocks eFFECTOR's I/O plans — although execs promise bigger slice of the NSCLC market in the long run
When eFFECTOR Therapeutics went public last summer on the coattails of a reverse merger with Locust Walk’s SPAC, the potential of its lead drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
